Have a feature idea you'd love to see implemented?
Let us know!
APRE Aprea Therapeutics Inc
Price (delayed)
$2.9228
Market cap
$15.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.81
Enterprise value
-$10.41M
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor
Highlights
The company's gross profit has surged by 130% YoY and by 2.8% QoQ
Aprea Therapeutics's revenue has soared by 130% YoY and by 2.8% from the previous quarter
APRE's EPS has dropped by 123% year-on-year but it is up by 7% since the previous quarter
The quick ratio has contracted by 22% from the previous quarter but it has grown by 19% YoY
Aprea Therapeutics's net income has decreased by 4.5% QoQ
Key stats
What are the main financial stats of APRE
Market
Valuations
Earnings
Shares outstanding
5.43M
Market cap
$15.89M
Enterprise value
-$10.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.72
Price to sales (P/S)
13.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-7.94
Revenue
$1.31M
EBIT
-$14.83M
EBITDA
-$14.81M
Free cash flow
-$13.81M
Per share
Balance sheet
Liquidity
EPS
-$2.81
Free cash flow per share
-$2.32
Book value per share
$4.04
Revenue per share
$0.22
TBVPS
$4.53
Total assets
$26.89M
Total liabilities
$4.95M
Debt
$0
Equity
$21.95M
Working capital
$22.85M
Debt to equity
0
Current ratio
7.28
Quick ratio
7.23
Net debt/EBITDA
1.78
Margins
Efficiency
Dividend
EBITDA margin
-1,129.8%
Gross margin
100%
Net margin
-1,030.4%
Operating margin
-1,126.6%
Return on assets
-47.9%
Return on equity
-57.9%
Return on invested capital
N/A
Return on capital employed
-63.8%
Return on sales
-1,131.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APRE stock price
How has the Aprea Therapeutics stock price performed over time
Intraday
-2.9%
1 week
-12.75%
1 month
-32.03%
1 year
-22.06%
YTD
-37.81%
QTD
6.28%
Financial performance
How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$1.31M
Gross profit
$1.31M
Operating income
-$14.77M
Net income
-$13.51M
Gross margin
100%
Net margin
-1,030.4%
The company's gross profit has surged by 130% YoY and by 2.8% QoQ
Aprea Therapeutics's revenue has soared by 130% YoY and by 2.8% from the previous quarter
The net margin has surged by 56% year-on-year
The company's operating margin has surged by 56% YoY
Growth
What is Aprea Therapeutics's growth rate over time
Valuation
What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
0.72
P/S
13.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-7.94
APRE's EPS has dropped by 123% year-on-year but it is up by 7% since the previous quarter
APRE's P/B is 68% below its 5-year quarterly average of 2.3 and 26% below its last 4 quarters average of 1.0
The equity has contracted by 14% from the previous quarter but it has grown by 8% YoY
Aprea Therapeutics's revenue has soared by 130% YoY and by 2.8% from the previous quarter
APRE's P/S is 39% below its last 4 quarters average of 22.4
Efficiency
How efficient is Aprea Therapeutics business performance
APRE's return on sales has surged by 55% year-on-year
Aprea Therapeutics's ROA has decreased by 5% YoY and by 3.5% from the previous quarter
The company's return on equity fell by 4.3% YoY and by 2.7% QoQ
Dividends
What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APRE.
Financial health
How did Aprea Therapeutics financials performed over time
The current ratio has decreased by 24% from the previous quarter but it has increased by 18% YoY
The quick ratio has contracted by 22% from the previous quarter but it has grown by 19% YoY
The debt is 100% smaller than the equity
The equity has contracted by 14% from the previous quarter but it has grown by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.